REC Ref No.	IRAS No.	Name of Trial	Date First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non- Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
20/WM/0115	278915	Solitaireâ,,¢ With the Intention For Thrombectomy Plus Intravenous t-PA Versus DIRECT Solitaireâ,,¢ Stent-retriever Thrombectomy in Acute Anterior Circulation Stroke			08/04/2020						Neither
20/EM/0115	282431	A randomised phase II proof of principle multi-arm multi- stage trial designed to guide the selection of interventions for phase III trials in hospitalised patients with COVID-19 infection		03/06/2020	05/06/2020		26/06/2020	26/06/2020		26/06/2020	
20/NE/0169	279315	A first-in-human clinical trial to assess the safety and immunogenicity of a self-amplifying ribonucleic acid (saRNA) vaccine encoding the S glycoprotein of SARS-CoV-2, the causative agent of COVID-19 - COVAC1			08/06/2020	11/06/2020		16/06/2020			
	265062	An open-label, non-randomized extension study to evaluate the long-term efficacy, safety and tolerability of LNP023 in subjects with C3 glomerulopathy		11/05/2020	08/06/2020		03/07/2020	16/07/2020		17/09/2020	
20/SC/0211	282109	Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV)	07/07/2020	01/05/2020	13/05/2020			22/05/2020		02/07/2020	
20/HRA/2068	283394	A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome		01/05/2020	01/05/2020		29/05/2020	21/05/2020		29/05/2020	
20/WM/0123	282099		22/04/2020	31/03/2020	07/04/2020	06/04/2020	15/04/2020	15/04/2020		17/04/2020	
20/NE/0105	282026	A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â,¢) in Participants with Moderate COVID-19 Compared to Standard of Care Treatment	10/04/2020	27/03/2020	31/03/2020		31/03/2020	06/04/2020		08/04/2020	
20/EE/0078	267074	A Phase 3 multicentre, double-blind, randomized, placebo- controlled study to evaluate the efficacy, safety, and tolerability of Rozanolixizumab in adult study participants with persistent or chronic primary immune thrombocytopenia (ITP)- TP0003		20/03/2020	25/03/2020						Neither
20/NE/0104	282007	A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â,,¢) in Participants with Severe COVID-19	09/04/2020	24/03/2020	31/03/2020		31/03/2020	06/04/2020		07/04/2020	
20/EE/0101	281712	Randomised Evaluation of COVID-19 Therapy	25/03/2020	16/03/2020	23/03/2020			25/03/2020		25/03/2020	

20/LO/0574	281827	Preventing Cardiac Complications of COVID-19 Disease with Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.	16/03/2020	26/03/2020	26/03/2020	02/04/2020	03/04/2020	03/04/2020	
	272955	Brain connectivity and patient reported outcomes in people with HIV with symptoms of insomnia switching integrase inhibitor-based ART; a randomised controlled study	02/03/2020	13/03/2020					Neither
	272571	Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy.		01/06/2020	17/07/2020				
20/YH/0077	272228	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy and Safety of VIS649 in Participants with Immunoglobulin A (IgA) Nephropathy	26/02/2020	26/02/2020					Neither
18/EE/0389	235758	Seizure PRophylaxis IN Glioma	21/02/2020	21/02/2020					Neither
20/SW/0018	272435	A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in combination with Gemcitabine Plus Nabpaclitaxel as Neoadjuvant Treatment in Patients with Locally Advanced, Unresectable Pancreatic Cancer	05/02/2020	30/03/2020	11/03/2020				Neither
20/NE/0014	272055	Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms in Kawasaki disease	20/02/2020	28/02/2020					Sponsor
19/WA/0358	271728	Pre-Hospital Zone 1 Partial Resuscitative Endovascular Balloon Occlusion of the Aorta for injured patients with exsanguinating sub-diaphragmatic haemorrhage.	23/01/2020	17/06/2020		17/06/2020	26/06/2020	26/06/2020	
	272768	A Randomised Multiple Centre Trial of Conservative versus Liberal Oxygenation Targets in Critically III Children	28/01/2020	28/01/2020	23/12/2019				Sponsor
	234635	Heme arginate in transplantation - a multi-centre blinded parallel-group randomised trial of heme arginate versus placebo to reduce delayed graft function in kidney transplant recipients	22/01/2020	23/01/2020					Neither
20/YH/0090	278137	AN OPEN-LABEL, MULTICENTER, ROLLOVER STUDY TO 27/08/2020 EVALUATE THE SAFETY AND TOLERABILITY OF LONG-TERM ADMINISTRATION OF GANTENERUMAB IN PARTICIPANTS WITH ALZHEIMER'S DISEASE	21/02/2020	05/05/2020		10/08/2020	13/08/2020	17/08/2020	
	260938	A Phase III, Randomized, Multicenter, Open-Label Study in Adolescent and Adult Participants Comparing the Efficacy and Safety of Gepotidacin to Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria gonorrhoeae	22/01/2020	11/02/2020					Neither
19/LO/1538	264933	A seamless phase Ib/II study of selective HDAC6 inhibition with KA2507 in advanced biliary tract cancer previously treated with standard of care chemotherapy (ABC-11)	19/12/2019	12/02/2020	27/01/2020				Sponsor

40/514/2222	los (so)	IAB I I I B II BE I BE I C I I I		15/44/2245	4.4/0.4/0.000		0.4/0.0/0.00	10/00/2000		45/04/2222	lo.
18/EM/0323	251531	A Randomized, Double-Blind, Placebo-Controlled,		15/11/2019	14/01/2020		04/03/2020	19/03/2020		15/04/2020	Sponsor
		Multicenter Study to Evaluate the									
		Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute									
		Graft-Versus-Host Disease in Subjects Undergoing									
		Allogeneic Hematopoietic Stem Cell									
		Transplantation									
20/EE/0031	275993	Multicenter, randomized, placebo-controlled, double-blind,		20/12/2019	31/01/2020						Neither
		parallel group, dose-finding Phase 2 study to evaluate			3.,0.,2020						
		efficacy and safety of BAY 2433334 in patients following an									
		acute noncardioembolic ischemic stroke									
20/LO/0364	274161	Minimally Invasive Realtime Assessment of Continuous		10/02/2020	28/02/2020	07/05/2020					Neither
		Lactate in Exercise (MIRACLE)									
19/NW/0707	272541	A Randomized, Double-Blind, Placebo-Controlled Phase 2		29/11/2019	08/01/2020						Neither
		Study Comparing the Efficacy and Safety of Tirzepatide									
		versus Placebo in Patients with Nonalcoholic Steatohepatitis									
10//////0075	244222	(NASH)		14/06/2012	20/04/2020	11/02/2010	11/05/2020				Maithar
18/WM/0275	211232	A prospective non-randomised multi-centre feasibility study to assess if patients with residual cancer following dual-		14/06/2019	28/01/2020	11/02/2019	11/05/2020				Neither
		targeted neoadjuvant chemotherapy treatment for HER2-									
		positive, ER-negative early breast cancer can be identified by									
		multiple ultrasound (US)-guided tumour bed core biopsies									
		(00) galasa (alloan soa solo siopoloo									
19/EM0258	266702	Fluids Exclusively Enteral From Day 1	05/03/2020	13/11/2019	09/01/2020	13/09/2019	09/01/2020	13/02/2020		18/02/2020	
19/WM/0297	266583	Safe and supported disclosure of sexual violence		10/02/2020	11/02/2020			10/03/2020			Neither
19/EE/0326	270902	A randomised double-blind placebo controlled phase 3 trial to		17/10/2019	28/10/2019		04/03/2020	10/03/2020			Sponsor
		evaluate the efficacy and safety of estetrol for the treatment									
		of moderate to severe vasomotor symptoms in									
00/10/2005	000050	postmenopausal women (E4 Comfort Study I)		00/40/2045	00/00/000						
20/LO/0029	260359	Ultrasound-guided High Intensity Focused Ultrasound to treat		03/12/2019	09/03/2020						Sponsor
19/YH/0351	270909	Twin-Twin Transfusion Syndrome (USgHIFU-TTTS)		14/10/2010	13/01/2020		24/01/2020	27/01/2020		20/01/2020	Neither
19/10/0351	270898	A phase 2, prospective, randomised, double-blind, placebo- controlled clinical study to assess the efficacy, safety,		14/10/2019	13/01/2020		24/01/2020	27/01/2020		30/01/2020	inellie
		tolerability, and pharmacokinetics of SJX-653 in									
		postmenopausal women with moderate to severe vasomotor									
		symptoms									
19/LO/1082	254912	ATr inhibitor in combination with olaparib in gynaecological		30/09/2019	12/12/2019	17/10/2019	04/09/2020	14/09/2020			Neither
		cancers with ARId1A loss or no loss									
19/NW/0462	251756	Chronic Endometriosis and Recurrent Miscarriage - The		10/10/2019	13/01/2020	20/08/2019					Sponsor
		CERM Trial									
19/LO/1532	269933	A Phase II, multicenter, randomized, open label two arm	1	18/09/2019	18/12/2019	06/12/2019	03/02/2020	04/02/2020		21/02/2020	Sponsor
	1	study comparing the effect of crizanilumab + standard of care		1							
											1
		alone on renal function in sickle cell disease patients ≥ 16									
		alone on renal function in sickle cell disease patients ≥ 16 years with chronic kidney disease due to sickle cell									
10/1 0/4022	266564	alone on renal function in sickle cell disease patients ≥ 16 years with chronic kidney disease due to sickle cell nephropathy		14/11/2010	30/01/2020	03/04/2020					Noithor
19/LO/1832	266564	alone on renal function in sickle cell disease patients ≥ 16 years with chronic kidney disease due to sickle cell nephropathy Is there an association between arterial spectral waveforms		14/11/2019	30/01/2020	03/01/2020					Neither
19/LO/1832	266564	alone on renal function in sickle cell disease patients ≥ 16 years with chronic kidney disease due to sickle cell nephropathy		14/11/2019	30/01/2020	03/01/2020					Neither

19/NW/0336	256297	Radiographic imaging Validation and EvALuation for Angio iFR (ReVEAL iFR)		30/09/2019	05/11/2019	07/08/2019	08/01/2020	20/01/2020	27/02/2020	Sponsor
18/WA/0005	223997	Phase III study assessing the "best of―radiotherapy compared to the "best of―surgery (trans-oral surgery (TOS)) in patients with T1-T2, N0-N1 oropharyngeal, supraglottic carcinoma and with T1, N0 hypopharyngeal carcinoma			23/12/2019	12/03/2018	26/08/2020			Neither
	254786	A NON-INTERVENTIONAL, MULTICENTER, MULTIPLE COHORT STUDY INVESTIGATING THE OUTCOMES AND SAFETY OF ATEZOLIZUMAB UNDER REAL-WORLD CONDITIONS IN PATIENTS TREATED IN ROUTINE CLINICAL PRACTICE			07/08/2019	06/08/2019	11/11/2019	14/11/2019		Sponsor
19/LO/1583	271866	A Phase 2, Open Label, Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Voxelotor in Patients with Sickle Cell Disease	12/12/2019	11/09/2019	18/11/2019	14/11/2019	15/11/2019	26/11/2019	28/11/2019	
19/LO/1566	267041	A Randomized, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Pharmacodynamics of Once-daily Oral IW-1701 in Patients with Stable Sickle Cell Disease		07/08/2019	21/11/2019	21/11/2019	10/12/2019	17/12/2019	21/02/2020	Sponsor
19/NE/0312	266862		20/02/2020	10/09/2019	15/11/2019	13/11/2019	06/01/2020	10/01/2020	10/01/2020	Sponsor
19/LO/1756	272037	A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma/ CA209-9DW			01/05/2020	30/06/2020	25/03/2020			
	266797	Evaluation of a single use point of care device for the diagnosis of influenza and other respiratory pathogens in clinical upper airway samples using isothermal amplification – a feasibility study.	24/02/2020	21/10/2019	21/02/2020	05/02/2020		21/02/2020	21/02/2020	
	234167	tolerability, pharmacokinetics and preliminary efficacy of CTX-SPL9111 (a cabazitaxel (CTX)-dendrimer conjugate) in patients with advanced solid tumours			12/11/2019	30/01/2018	06/01/2020	09/01/2020		Sponsor
18/WS/0187	242800	Retrospective and prospective international EKoSoNic® registry Of the treatment and Clinical OUTcomes of patients with Pulmonary Embolism	12/02/2020		11/12/2019	29/11/2018	13/12/2019	12/12/2019	13/12/2019	
19/SC/0415	269249	A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY)		03/05/2019	20/08/2019	04/10/2019	15/10/2019	23/10/2019		Sponsor

10/00/01440	1000050	In 1 0/0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	1	05/00/0040	04/00/0040		4.4/4.0/0.04.0	00/40/0040		lo.
19/SC/0416	269256	A phase 2/3 randomised, double-blind, palivizumab-		05/03/2019	21/08/2019		14/10/2019	23/10/2019		Sponsor
		controlled study to evaluate the safety of MEDI8897, a								
		monoclonal antibody with an extended half-life against								
		respiratory syncytial virus, in high risk children (MEDLEY)								
19/LO/1694	260260	A Phase 1/2 Open-Label, Multi-Center, First-in-Human Study		17/07/2019	14/12/2019	13/12/2019	27/01/2020	31/01/2020	31/01/2020	Sponsor
		of the safety, toleraribility pharmacokinetics, and Anti-tumor								
		activity of TPX-0005 in PAtients with Advanced Solid Tumors								
		Harboring ALK, ROS1, or NTRK1-3 Rearrangments								
19/LO/1630	261244	Haemodynamic changes in femoral-popliteal bypass grafts	27/02/2020	24/07/2019	21/11/2019	11/11/2019		10/02/2020	11/02/2020	Sponsor
		with the use of neuromuscular electrical stimulation								
19/LO/0555	255609	Lateral compression type-1 fracture fixation in the elderly, a		12/08/2019	03/09/2019	17/07/2019	03/09/2019	26/09/2019	17/10/2019	Neither
		randomised controlled trial - L1FE								
20/SC/0081	265850	Feasibility of identifying autonomic drivers for human Atrial		19/02/2020	03/06/2020	21/04/2020	24/02/2020	27/07/2020	27/07/2020	
		Fibrillation								
19/LO/1441	269042	Assessment of wearable sensors during experimental human	11/02/2020	12/08/2019	05/02/2020	10/12/2019	12/08/2019	07/02/2020	07/02/2020	
		influenza infection (Sigma Plus)								
19/LO/1726	269978	A diagnostic accuracy study evaluating point of care gastric	11/03/2020	19/07/2019	19/12/2019	18/12/2019	10/02/2020	04/03/2020	04/03/2020	Sponsor
		lipase enhanced pH test strip to confirm correct nasogastric								
		tube position in newborn infant								
19/LO/1585	263041	Compression Hosiery to Avoid Post-Thrombotic Syndrome	10/03/2020	28/05/2019	03/02/2020	24/10/2019	19/12/2019	04/02/2020	19/02/2020	
19/LO/1540	269196	Bariatric surgery vs. Medical care for obesity and polycystic	28/02/2020	24/07/2019	28/10/2019	10/12/2019	24/07/2019	06/02/2020	06/02/2020	Neither
		ovarian syndrome related infertility:						00,02,202		
		The BAMBINI randomised-controlled clinical trial								
19/ES/0095	268796	A Multicenter, Randomized, Double Blind, Placebo-		24/07/2019	01/11/2019			10/11/2019	11/11/2019	Sponsor
		Controlled, Phase 3 Study to Determine if RTB101 Prevents								
		Clinically Symptomatic Respiratory Illness in the Elderly								
19/EE/0164	261589	T-cell Lymphoma anti-KIR3DL2 therapy. An open label, multi-		12/07/2019	07/08/2019	19/07/2019	12/12/2019	18/12/2019	16/01/2020	Sponsor
		cohort, multi-center phase II study evaluating the efficacy					,,			-
		and safety of IPH4102 alone or in combination with								
		chemotherapy in patients with advanced T-cell lymphoma.								
19/LO/1263	263485	A Randomized, Double-Blind, Controlled Phase 3 Study of		25/02/2019	04/09/2019	04/09/2019	14/01/2020	18/02/2020		Sponsor
		Cabozantinib in Combination with Nivolumab and Ipilimumab								-1
		versus Nivolumab and Ipilimumab in Subjects with								
		Previously Untreated Advanced or Metastatic Renal Cell								
		Carcinoma of Intermediate or Poor Risk								
19/ES/0136	270742	A Randomized, Double-Blind, Phase 3 Study to Evaluate the		05/07/2019	29/11/2019	16/01/2020	20/03/2020	25/03/2020		Sponsor
2, = 2, 0.00		Activity of Momelotinib (MMB) versus Danazol (DAN) in								
		Symptomatic, Anemic Subjects with Primary Myelofibrosis								
		(PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post								
		Essential Thrombocythemia (ET) Myelofibrosis who were								
		Previously Treated with JAK Inhibitor Therapy.								
19/LO/1215	261663	A Phase 3b, open-label, single-arm, rollover study to		16/07/2019	16/07/2019	11/02/2020				Sponsor
1.0,20,1210		evaluate long-term safety in subjects who have participated		10,01,2010	. 5, 5, 72 5 1 5	11,02,2020				
		in other luspatercept (ACE-536) clinical trials.								
<u> </u>	l	in ourse respectively (NOE 000) chinical thats.	ļ	ļ.						I

19/LO/0787	258456	A Phase 3, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Fedratinib Compared to Best Available Therapy in Subjects with DIPPS-Intermediate or High-risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated with Ruxolitinib.		29/05/2019	09/12/2019	20/09/2019	06/01/2020	13/01/2020	31/01/2020	Neither
19/NW/0135	252254	An International Randomised Clinical Trial of Therapeutic Interventions with the Potential to Improve Outcome in Adults with Acute Myeloid Leukaemia and High Risk Myelodysplasia Undergoing Allogeneic Stem Cell Transplantation.	2	26/06/2019	08/01/2020	17/05/2019	25/03/2020	11/06/2020	27/07/2020	Sponsor
19/NW/0328	263312	A Phase 2 Randomized, Double-Blind, Placebo Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Ulcerative Colitis		04/07/2019	30/10/2019		04/07/2019	08/11/2019	21/01/2020	Neither
19/LO/1153	262506	A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia		18/06/2019	17/09/2019	16/09/2019	10/10/2019	17/10/2019	15/11/2019	Neither
19/LO/0201	248593	Rivaroxaban versus warfarin for stroke patients with antiphospholipid syndrome, with or without SLE (RISAPS): a randomised, controlled, open-label, phase II/III, non-inferiority trial		04/02/2019	11/03/2020	24/06/2019				Sponsor
19/LO/1449	269837	Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced/Unresectable Biliary Tract Carcinoma		04/07/2019	28/04/2020	24/03/2020				
20/LO/0496	262552	Phase 1/1b Study of Intratumorally Administered STING Agonist E7766 in Subjects With Advanced Solid Tumors or Lymphomas		29/05/2019	04/05/2020	03/07/2020	13/09/2020	15/09/2020		
20/NW/0054	274432	Placebo-controlled Trial of Pembrolizumab in Esophageal Carcinoma Participants Receiving Concurrent dCRT - MK3475 KN 975		07/11/2019	18/06/2020	31/03/2020	07/11/2019	13/08/2020		
17/LO/0871	215297	Methylphenidate versus placebo for fatigue in advanced cancer		15/05/2019	29/10/2019	23/05/2018		11/03/2020		Sponsor
18/NE/0360	254062	An open-label, non-randomised study on efficacy, pharmacokinetics, pharmacodynamics, safety and tolerability of LNP023 in two patient populations with C3 glomerulopathy	1/03/2020	17/06/2019	30/09/2019		30/09/2019	14/11/2019	11/12/2019	Sponsor
19/LO/1152	265415	A phase 2, open-label, single-arm, multicenter study to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumor malignancy harboring activating FGFR mutations and translocations		02/05/2019	24/09/2019	16/08/2019	22/11/2019			Sponsor

40/10/4000	loccooo	The DIO Trials A year density of a controlled trial of decolled a	ı	4.4/04/0000	4.4/04/0000	40/40/0040				Ni a itia a n
19/LO/1669	266322	The RIO Trial: A randomised controlled trial of dual long-		14/01/2020	14/01/2020	12/12/2019				Neither
		acting HIV-specific broadly neutralising antibodies (bNAbs)								
		vs ART-only in treated primary HIV infection - A two-stage								
		randomised phase II placebo controlled clinical trial					.=	2=12.1.12.22		
19/LO/0943	264067	A Phase 3, Randomized, Double-blind Study to Evaluate		30/11/2018	02/12/2019		17/12/2019	07/01/2020	12/03/2020	Sponsor
		Perioperative								
		Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy								
		versus Perioperative Placebo +								
		Neoadjuvant Chemotherapy in Cisplatin-eligible Participants								
		with Muscle-invasive Bladder								
		Cancer (KEYNOTE-866)								
19/WS/0015	257933	A Phase 2, Multi-Center, Randomized, Double-Blind,		05/11/2018	10/12/2019		03/01/2020	04/02/2020	17/02/2020	Sponsor
		Placebo Controlled, Parallel Group Study to Evaluate the								
		Efficacy and Safety of T-817MA in Patients with Mild								
		Cognitive Impairment Due to Alzheimer's Disease or Mild								
		Alzheimer's Disease								
19/NE/0247	259906	A Phase 2, Double-blind, Active-controlled, Dose-titrating		27/11/2019	24/02/2020	17/12/2019	20/05/2020			Neither
		Efficacy and Safety Study of Firibastat (QGC001) Compared								
		to Ramipril Administered Orally, Twice Daily, Over 12 Weeks								
		to Prevent Left Ventricular Dysfunction after Acute								
		Myocardial Infarction								
19/LO/1393	266410	Embotrap extraction & clot evaluation & lesion evaluation for		07/05/2019	17/06/2020	17/11/2019	27/07/2020			
		neurothrombectomy								
19/SC/0272	261974	A Placebo-Controlled, Double-Blind, Parallel-Group, 18-	13/11/2019	27/05/2019	03/09/2019		17/09/2019	17/09/2019	23/09/2019	Neither
		Month Study With an Open-Label Extension Phase to								
		Confirm Safety and Efficacy of BAN2401 in Subjects With								
		Early Alzheimer's Disease								
19/LO/0879	264047	MK3475-905: A Phase 3 Randomized Study of Cystectomy		19/12/2018	09/08/2019		17/12/2019	07/01/2020		Sponsor
		plus Perioperative Pembrolizumab versus Cystectomy Alone								
		in Cisplatin-ineligible Participants with Muscleinvasive								
		Bladder Cancer (KEYNOTE-905)								
17/NW/0581	214739	Does Interleukin-1 Receptor Antagonist Improve Outcome		17/04/2019	15/10/2019					Neither
		following aneurysmal Subarachnoid Haemorrhage (aSAH)?								
		A Phase III trial								
19/SC/0073	246299	Segmental Tibial fractures, reamed Intramedullary nailing		17/04/2019	18/07/2019	02/05/2019	05/07/2019	19/07/2019	22/07/2019	Neither
		versus circular Frame external Fixation – A Feasibility								
		study								
19/NE/0137	258746	An Open-Label, Multicenter, Extension Study of AG-348 in		14/01/2019	23/07/2019	12/06/2019	21/08/2019	30/08/2019	01/10/2019	Sponsor
		Adult Subjects With Pyruvate Kinase Deficiency Previously								
		Enrolled in AG-348 Studies								
19/LO/1290	262104	Non-Invasive Continuous Cardiac Output Monitoring in	24/10/2019	11/02/2019	03/10/2019	02/10/2019	03/10/2019	03/10/2019		
		Newborn Infant Study								
19/LO/1018	262987	The FLIP-1 Study: Feasibility, safety, tolerance and	16/09/2019	15/05/2019	04/09/2019	04/09/2019	11/09/2019	11/09/2019	12/09/2019	
		assessment of LACTIN-V use in a cohort of pregnant women								
		at increased risk of preterm birth.								
19/LO/1341	256276	The Impact of Real-time Continuous Glucose Monitoring on			17/12/2019	21/02/2020		18/12/2019		Neither
		Glycaemic Control in High-risk Adolescents and Young								
		Adults with Insulin-treated Diabetes								
		!								

19/EE/0168	262098	A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011)		22/10/2018	17/07/2019	16/07/2019	05/08/2019	06/11/2019	12/12/2019	Sponsor
19/LO/0881	257058	Feasibility study of OnTrack - a digital system for upper limb rehabilitation after stroke		16/04/2019	11/07/2019	10/07/2019		31/07/2019		Sponsor
19/LO/1363	263653	Stryker ASSIST Registry		19/03/2019	19/11/2019	19/11/2019	22/11/2019	27/11/2019		Neither
18/EM/0310	239782	Emergency Cervical Cerclage to Prevent Miscarriage and Preterm Birth - a Randomised Controlled Trial		11/03/2019	31/01/2020	16/01/2019				Sponsor
18/LO/1022	233151	An open-label, randomised, phase II trial of ruCaparib combined with Nivolumab +/- Ipilimumab to augment response in homologous repair deficient patients with relapsed Ovarian, primary peritoneal and fallopian tube cancer		06/02/2019	26/02/2020	14/05/2019	06/02/2019			Sponsor
19/LO/0785	251807	Nonavalent prophylactic HPV vaccine (GARDASIL9) after local conservative treatment for cervical intra-epithelial neoplasia: a randomised controlled trial – The NOVEL trial		21/03/2019	27/08/2019	22/07/2019	03/03/2020	11/03/2020	12/03/2020	NHS Provider
19/LO/1320	255755	Mechanisms of adverse effects of long-acting beta-agonists in asthma (MAELABA)		06/08/2019	13/08/2019	02/12/2019				Sponsor
19/LO/0216	227201	A crossover, cluster randomised controlled trial of Selective Decontamination of the Digestive Tract in Intensive Care Unit patients (SuDDICU)	19/11/2019	19/02/2019	19/09/2019	19/09/2019	23/09/2019	08/11/2019	08/11/2019	
19/LO/1758	255860	Validation of beat-to-beat wavefront direction using omnipolar mapping in human atrial flutter. (ATrial flutter Omnipolar Mapping - ATOM)	18/06/2020	12/11/2019	28/01/2020	17/01/2020	23/01/2020	15/06/2020	08/07/2020	Neither
19/LO/1529	259691		11/12/2019	12/02/2019	13/11/2019		12/02/2019	03/12/2019	03/12/2019	
17/WS/0210	231280	A placebo controlled randomised trial of intravenous lidocaine in accelerating gastrointestinal recovery after colorectal surgery		11/02/2019	19/08/2019	27/04/2018	26/11/2019	03/12/2019	20/12/2019	Both
18/SC/0262	207163	Phase Ilb, randomised, double-blind, placebo-controlled, multi-centre trial of infliximab with transcriptomic biomarker and mechanism evaluation in patients with acute pancreatitis		25/09/2019	07/01/2020	15/08/2018	25/11/2019	09/01/2020	04/03/2020	Sponsor
19/LO/0637	258758	Ripple Mapping Guided Ablation for Atrial Tachycardia: The Ripple AT-Plus Study	01/11/2019	25/03/2019	01/10/2019	14/06/2019		03/10/2019	08/10/2019	
19/NW/0342	264974	A Phase 3/4, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)		24/06/2019	08/01/2020		27/01/2020	31/01/2020	31/01/2020	Neither

18/NE/0210	223922	The Management for Adults with Chronic RhinOsinusitis (MACRO)	27/01/2020	25/01/2019	26/07/2019	20/07/2018	30/07/2019	13/09/2019	10/10/2019	Sponsor
19/LO/0712	257246	Comparative Health Research Outcomes of NOvel Surgery in prostate cancer	08/01/2020	07/11/2019	14/11/2019	07/08/2019	07/11/2019	11/12/2019	11/12/2019	
19/NS/0052	258885	A feasibility study to evaluate the use of digital technologies and artificial intelligence (AI) to enhance surgical team training and performance in the operating theatre and to improve efficiency and patient outcomes.	04/10/2019	02/04/2019			12/07/2019	23/09/2019	23/09/2019	
18/LO/1817	244726	A Phase 1b, Multicenter, Two-Part, Open-Label Study of DS-8201a, an Anti-Human Epidermal Growth Factor Receptor- 2 (HER2)-Antibody Drug Conjugate (ADC), in Combination with Nivolumab, an Anti-PD-1 Antibody, for Subjects with HER2-Expressing Advanced Breast and Urothelial Cancer		28/11/2018	26/07/2019	26/04/2019	28/10/2019	13/11/2019		Sponsor
19/LO/0431	253404	Assessment of the Accuracy of Continuous Glucose Sensors in People with Diabetes Undergoing Haemodialysis	11/12/2019	13/12/2018	10/07/2019		13/12/2018	29/07/2019		Sponsor
19/LO/1183	259840	IPX203-B16-02		14/12/2018	26/11/2019			03/01/2020	21/01/2020	Neither
19/LO/0660	253405	A Phase 2b/3 study to evaluate the safety, tolerability, and effects of Livoletide (AZP-531), an unacylated ghrelin analog, on food-related behaviors in patients with Prader-Willi syndrome	14/11/2019	26/10/2018	01/10/2019			16/10/2019	21/10/2019	
19/LO/0063	255904	A StuDy EVAluatiNg the Long-Term EffiCacy and Safety of RalinEpag in Subjects with PAH via an Open-Label EXTENSION		24/04/2020	01/06/2020					
19/LO/0062	255909	A study evaluating the efficacy and safety of ralinepag to improve treatment outcomes in PAH patients.		24/04/2020	17/06/2020					
19/SC/0350	266934	A Phase 1B, Randomized, Subject- and Investigator-Blinded, Placebo-Controlled, Multi-Center Clinical Trial to Evaluate the Safety and Pharmacokinetics of Inhaled GB002, and Assess Changes in Imaging and Biomarkers in Subjects with WHO Group 1 Pulmonary Arterial Hypertension (PAH)		30/10/2018	25/09/2019	17/09/2019	24/09/2019	27/11/2019	27/11/2019	Sponsor
18/SS/0085	243640	Alpha 2 agonists for sedation to produce better outcomes from critical illness (A2B Trial): A randomised, parallel group, allocation concealed, controlled, open, phase 3 pragmatic clinical and cost- effectiveness trial with internal pilot	08/10/2019	12/10/2018	08/07/2019	12/11/2018	31/01/2019	12/08/2019	19/09/2019	Sponsor
19/LO/0987	260311	Thoracoabdominal branch endoprosthesis		28/01/2019	14/10/2019					Neither
19/LO/0767	250759	EMBO-PMS: Post Market Surveillance of the IMPEDE Embolization Plug System Protocol CRD 1005	20/09/2019	11/10/2018	01/07/2019	29/05/2019	19/06/2019	08/07/2019	08/07/2019	Neither
18/LO/1810	252582	Randomised feasibility trial of an onward HIV disclosure intervention for 18-25 year olds living with perinatally acquired HIV	09/10/2019	28/08/2018	04/07/2019		01/04/2019	13/08/2019	13/08/2019	Neither
19/LO/0699	252712	Tigertriever Revascularization Device Registry	07/02/2020	01/10/2018	29/08/2019	28/08/2019	26/06/2019	25/09/2019	25/09/2019	Neither
19/WA/0005	246081	Additional Treatments to the Local tumour for metastatic prostate cancer: Assessment of Novel Treatment Algorithms	26/09/2019	16/09/2018	30/07/2019	14/03/2019	30/07/2019	24/09/2019	26/09/2019	

	234266	Efficacy of propofol-supplemented cardioplegia on biomarkers of organ injury in patients having cardiac surgery using cardiopulmonary bypass: Propofol cardioplegia for myocardial protection randomised controlled trial: the PROMPT2 Study			21/01/2020	24/10/2018	02/03/2020	06/03/2020	11/03/2020	Neither
18/SC/0399	237494	Re-evaluating Optimal Vaccine Schedules Against Ebola	03/10/2019	31/08/2018			05/09/2019	09/09/2019	25/09/2019	
18/LO/1400	250545	A prospective study to assess the efficacy and safety of the BlueWind RENOVA iStimâ,¢ system for the treatment of patients diagnosed with overactive bladder		18/07/2018	30/10/2019					Sponsor
17/EM/0440	230556	A randomised phase III trial to evaluate the Duration of ANti-PD1 monoclonal antibody Treatment in patients with metastatic mElanoma			23/10/2019	24/05/2018	20/12/2019	17/01/2020		Sponsor
19/LO/0249	242498	CHOlesterol Reduction with Evolocumab and coronAry microvascuLar function	16/09/2019	13/03/2019	19/07/2019	13/06/2019	16/08/2019	20/08/2019	11/09/2019	
18/WS/0180	246860	F-18 Fluoro-L-Thymidine PET for assessment of treatment Response to Immunotherapy Cancer	06/10/2019	04/06/2019	09/07/2019	02/04/2019	09/07/2019	25/07/2019	25/07/2019	Sponsor
18/LO/0660	237150	Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia	12/04/2020	26/03/2020	26/03/2020	23/07/2018	26/03/2020	09/04/2020	09/04/2020	
18/LO/1101	233138	Health in Pregnancy	30/10/2019	11/05/2018	22/07/2019	02/08/2018	26/09/2019	26/09/2019	26/09/2019	Neither
19/LO/0817	235449	A Phase II, Open-Label, Randomized, Multi-Centre Study, of Neoadjuvant Olaparib in Patients with Platinum Sensitive Recurrent High Grade Serous Ovarian/Primary Peritoneal or Fallopian tube Cancer		03/09/2019	03/09/2019	31/10/2019	07/11/2019	07/11/2019	20/11/2019	Sponsor
18/WM/0006	225197	An Adaptive, Sequential Evaluation of Powered and Manual Circular Staplers in Left-Sided Colorectal Anastomoses	27/11/2019	29/11/2017	03/07/2019	24/04/2019	15/11/2019	20/11/2019	20/11/2019	Sponsor
17/SC/0434	209815	BiomArker-guided Duration of Antibiotic treatment in hospitalised PaTients with suspected Sepsis: the ADAPT-Sepsis Trial.		28/09/2017	17/07/2019	23/10/2017				Sponsor
19/LO/1253	264253	The TARGET BP I Trial: A Phase 2, Multicenter, Double-Blinded, Sham-Procedure Controlled Trial of Renal Denervation by the Peregrine Systemâ, Kit, in Subjects with Hypertension		18/02/2020	25/02/2020	19/11/2019				Neither
17/LO/0170	219026	Accu-Chek® Diaport Observational Study.		25/03/2019	25/07/2019			07/08/2019		Neither
12/LO/0515	95626	Optimal Personalised Treatment of early breast cancer using Multiparameter Analysis		29/07/2015	09/10/2019	03/08/2016	02/03/2020	16/07/2020	30/07/2020	Sponsor